New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This new fund is amongst the largest for the sector in India
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Subscribe To Our Newsletter & Stay Updated